The therapy demonstrated good tolerability across all assessed cohorts, with no reports of serious or severe treatment-emergent adverse events. Credit: PeopleImages / Shutterstock.com. SCYNEXIS has ...
While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...
Metsera said the Phase III trial should be initiated by the end of 2025. Image credit: Alones / Shutterstock.com. Pfizer’s $4.9bn bet on obesity startup Metsera is looking promising, with 14.1% weight ...
ACL Digital will also be able to drive digital transformation for biotech, pharmaceutical and medical device companies. Credit: tilialucida / Shutterstock.com. ACL Digital has acquired US-based ...
On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...
Though Eli Lilly has shelved the obesity and T2D trial involving Zepbound, the US pharma will continue its obesity-only trial ...
PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing ...
Anebulo prioritised developing selonabant IV formulation as a potential treatment for paediatric patients with acute cannabis toxicity. Credit: murat photographer / Shutterstock.com. Anebulo ...
Pi Health is to deliver outsourced clinical research services in a GSK oncology study to enhance the efficiency and speed of ...
Bayer Latin America VP Luiz Barberini argued in favour of increased collaboration and transparency with clinical trial suppliers. Credit: Athanasios Psimadis / Arena International Events. Closer ...
atai Life Sciences and Beckley Psytech’s psychedelic has demonstrated significant efficacy in a Phase IIa trial, meaning the companies will now progress BPL-003 (intranasal mebufotenin benzoate) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback